The TIGIT trail has proved to be a tricky ... which combines its PD-1 inhibitor Opdivo (nivolumab) with LAG-3 drug relatlimab. That is approved for melanoma, but failed a phase 3 trial in MSS ...

BMS, which snapped up a TIGIT class cancer drug from Agenus ... Tumours fight off the attack by stimulating LAG-3 and PD-1, causing the white blood cells to become exhausted.

The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors�reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...

The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...

1 Department of Orthopedics, Central Hospital Affiliated to Shandong First Medical University, Jinan, China 2 Laboratory Medicine, Central Hospital Affiliated to Shandong First Medical University, ...

However, beyond PD-1/PD-L1 and CTLA-4 ... These include lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), T cell immunoreceptor with Ig and ...

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...

A team of researchers from Cleveland Clinic Genomic Medicine share insights from an early set of 19,000 patients to receive ...

Microglia are brain-resident macrophages playing pivotal roles in CNS development and homeostasis. Yet, the cellular and molecular basis governing microglia maintenance ...